Medicare Prices Myriad's BRACAnalysis, Colaris Tests; Firm Confirms Guidance for 2013 | GenomeWeb

NEW YORK (GenomeWeb News) – Following pricing on the BRACAnalysis and Colaris tests from Medicare contractor Noridian Administrative Services, Myriad Genetics on Friday said that total revenues and diluted EPS for fiscal 2013 are expected to be at the high end of previously issued guidance.

The Salt Lake City-based company previously guided to revenues of between $575 million and $585 million and EPS of between $1.55 and $1.58.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.